FDA wants to improve the ANDA first-cycle approval rate, but Janet Woodcock said cutting the number of cycles to two would be a desirable near-term goal for the Office of Generic Drugs.
Rather than pushing for first-cycle approvals, Woodcock, director of FDA’s Center for Drug Evaluation and Research, suggested during the June Generic Pharmaceutical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?